Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Tigecycline (mesylate)

Catalog No: tcsc1878

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Specifications

CAS No:
1135871-27-0

Formula:
$C_{30}H_{43}N_5O_{11}S$

Pathway:
Anti-infection

Target:
Bacterial

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Alternative Names:
GAR-936 mesylate

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
681.75

Product Description

Tigecycline mesylate a first-in-class, broad spectrum antibiotic with activity against antibiotic-resistant organisms.

Target: Antibacterial

Tigecycline mesylate is active against a broad range of gram-negative and gram-positive bacterial species including clinically important multidrug-resistant nosocomial and community-acquired bacterial pathogens. Tigecycline mesylate has been shown to inhibit the translation elongation step by binding to the ribosome 30S subunit and preventing aminoacylated tRNAs to accommodate in the ribosomal A site [1]. Tigecycline mesylate has also been found to be effective for the treatment of community- as well as hospital-acquired and ventilator-associated pneumonia and bacteremia, sepsis with shock and urinary tract infections. Tigecycline mesylate appears to be a valuable treatment option for the management of superbugs, especially where conventional therapy has failed [2].

Fifteen patients received tigecycline mesylate for 16 episodes of CPKP infection. The main infections were pneumonia (31%), urinary tract infection (31%), peritonitis (20%), catheter-related bacteraemia (12%), and meningitis (6%). Most infections were complicated with severe sepsis (44%), septic shock (12%), and/or bacteraemia (19%). The daily maintenance dose of tigecycline mesylate was 200 mg in 10 episodes and 100 mg in 6 episodes. The overall 30-day mortality rate was 25%. Univariate analysis showed that mortality was significantly associated (p
Clinical indications: Acinetobacter infection; Bacterial infection; Bacterial pneumonia; Bacterial skin infection; Bacteroides fragilis infection; Bacteroides infection; Citrobacter infection; Clostridiaceae infection; Clostridium difficile infection; Clostridium infection; Enterobacter infection

FDA Approved Date: June 17, 2005

Toxicity: nausea; vomiting; diarrhea; local IV-site reaction; infection; fever; headache